Product Information
DARIFENACIN ER 7.5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.5494 per EA under NDC 16571076709. Its NADAC has been published 227 times since Jun 1, 2022.
FDA first approved this application on Sep 19, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
7.5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571076709
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DARIFENACIN HYDROBROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206743FDA Approved
9/19/2016
TE Code
AB
On Market Since
9/19/2016
Pharmacological Classes
Price Statistics
The NADAC for DARIFENACIN ER 7.5 MG TABLET has been published 227 times since Jun 1, 2022, and over the history we have for it it has declined 70.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5494 per EA |
|---|---|
| All-time high | $2.0661 (Jul 13, 2022) |
| All-time low | $0.5115 (Aug 20, 2025) |
| 52-week high | $0.7315 |
| 52-week low | $0.5331 |
| Median price | $0.7764 |
| Average price | $0.9713 |
| Largest weekly change | +65.1% (Nov 22, 2023) |
| Weeks tracked | 227 |
| Tracking since | Jun 1, 2022 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 7% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Darifenacin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DARIFENACIN ER 7.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DARIFENACIN ER 7.5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.5494 per EA (NDC 16571076709), effective Sep 30, 2026.
How has the price of DARIFENACIN ER 7.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for DARIFENACIN ER 7.5 MG TABLET has declined 70.0%. It has been tracked across 227 weekly CMS publications since Jun 1, 2022.
What are the highest and lowest recorded NADAC prices for DARIFENACIN ER 7.5 MG TABLET?
Since Jun 1, 2022, the NADAC for DARIFENACIN ER 7.5 MG TABLET has ranged from a low of $0.5115 (Aug 20, 2025) to a high of $2.0661 (Jul 13, 2022), with a median of $0.7764 per EA.
Are there cheaper alternatives to DARIFENACIN ER 7.5 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DARIFENACIN ER 7.5 MG TABLET, is $0.5115 per EA — about 7% below DARIFENACIN ER 7.5 MG TABLET.
Who manufactures DARIFENACIN ER 7.5 MG TABLET?
DARIFENACIN ER 7.5 MG TABLET (NDC 16571076709) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.